Abstract
The present study evaluated the real-world effectiveness of influenza and pneumococcal dual-vaccination among Chinese elderly, the evidence on which was absent. Outpatient and inpatient claims databases from Jan 1, 2015 to Apr 1, 2017 of persons at least 60 years old in Shenzhen, China were merged with electronic records of influenza vaccines and 23-valent pneumococcal polysaccharide vaccines (PPSV23) from Oct 1, 2016 - May 31, 2017. Individuals who were vaccinated with influenza between Nov 1 and Dec 31, 2016 and received PPSV23 30 days within the date of influenza vaccination were defined as the vaccinated group. A control group consisted of individuals that received neither of the vaccines was constructed by matching on year of birth, sex, and district. The two outcomes were all-cause and acute respiratory hospitalizations. Difference-in-difference (DiD) logistic regressions that were proceeded with an entropy balancing (EB) process were used to analyse the effectiveness of dual-vaccination. A total of 48,116 eligible individuals were identified in the vaccinated group, which were matched by 93,692 individuals in the control group. The EB-DiD analyses estimated that dual-vaccination was associated with lower short-term risks...Continue Reading
References
Oct 5, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan F N HungKwok-Yung Yuen
May 9, 2012·The Journal of Infection·Yu-Chia ChangNicole Huang
Dec 12, 2012·Health Services Research·John M Brooks, Robert L Ohsfeldt
Feb 19, 2013·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Ivan Fan-Ngai HungRicardo Zotomayor
Feb 28, 2013·Human Vaccines & Immunotherapeutics·Aba MahamatBenoît de Wzieres
Jul 11, 2014·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·ShanLian HuCraig S Roberts
Dec 10, 2014·JAMA : the Journal of the American Medical Association·Justin B Dimick, Andrew M Ryan
Dec 30, 2014·Clinical and Vaccine Immunology : CVI·Joon Young SongWoo Joo Kim
Feb 13, 2015·The Lancet Infectious Diseases·Hector S IzurietaJeffrey Kelman
Jul 3, 2016·Applied Health Economics and Health Policy·Huanxue ZhouYunfeng Li
Sep 16, 2016·Human Vaccines & Immunotherapeutics·Yan-Yang ZhangBi-Rong Dong
Sep 30, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Hanna NohynekJukka Jokinen
Oct 14, 2016·Health Affairs·Sachiko OzawaPallavi D Patwardhan
Oct 27, 2016·Vaccine·Juan YangHongjie Yu
May 18, 2017·Journal of Public Health Policy·Yi ZhangChandini Raina MacIntyre
May 24, 2017·Clinical Epidemiology·Katherine E MuesDavid T Gilbertson
Jul 12, 2017·Annals of Internal Medicine·Tyler J VanderWeele, Peng Ding
Aug 22, 2017·Medical Decision Making : an International Journal of the Society for Medical Decision Making·David M PhillippoNicky J Welton
Jan 13, 2018·Annual Review of Public Health·Coady WingRicardo A Bello-Gomez
Jul 3, 2018·Expert Review of Vaccines·Mingjuan YinJindong Ni
Aug 3, 2019·Emerging Microbes & Infections·Weifeng ShiDayan Wang
Sep 9, 2019·The Lancet. Public Health·Li LiHongjie Yu
Mar 20, 2020·BMC Public Health·Yuheng WangMatthew L Boulton
Apr 2, 2020·Aging Medicine·Qiong ChenUNKNOWN Recommendations for Influenza, Streptococcus pneumoniae Vaccination in Elderly People in China Writing Group, Geriatric Resp
Apr 2, 2020·Aging Medicine·Xin Li, Sean X Leng
Jun 12, 2020·JAMA : the Journal of the American Medical Association·Lawrence O Gostin, Daniel A Salmon